Eduard Verhagen, John Lantos
5 min
As of February 2024, the Netherlands expanded its regulatory framework to allow euthanasia for children aged 1–12 years, building upon existing practices for adults and neonates. The Dutch approach is distinct because it does not legalize euthanasia in the traditional sense; rather, it maintains that the act remains technically illegal while providing a pathway for physicians to perform it without prosecution, provided they adhere to rigorous due-care criteria and undergo mandatory post-hoc review.
The Dutch model was significantly shaped by the 'Groningen Protocol,' developed in the early 2000s to standardize neonatal euthanasia. This protocol established clear criteria—such as unbearable suffering, parental consent, and independent physician consultation—to ensure transparency. Contrary to fears of a 'slippery slope' toward widespread euthanasia of disabled infants, the formalization of these guidelines was followed by a dramatic decline in the number of reported cases. This reduction is attributed to improved prenatal screening for congenital conditions and the rapid expansion of pediatric palliative care (PPC) programs, which effectively address suffering without the need for active life-ending interventions.
The expansion to children aged 1–12 years follows a similar logic: it is intended as a last resort for cases where palliative care fails to alleviate intractable suffering. The Dutch system emphasizes that moral ambiguity is inherent in end-of-life decisions; therefore, the goal is not to eliminate this ambiguity through rigid formulas, but to manage it through a process of public discussion, professional guidelines, and ongoing revaluation. By requiring every case to be reported to regional oversight committees, the Dutch government ensures that practice remains visible and accountable, allowing for adjustments as societal norms and medical capabilities evolve.
This paper provides a critical look at how a society can navigate the deeply controversial intersection of medical duty, patient suffering, and legal regulation. For researchers and policymakers, the Dutch experience demonstrates that it is possible to create a system that balances the protection of vulnerable populations with the compassionate relief of suffering. It highlights that the success of such a model depends less on the act of legalization itself and more on the robustness of the oversight mechanisms, the quality of available palliative care, and a commitment to continuous, transparent evaluation.
I
Sam: [steady] That's the authors' argument. The Dutch model works, they contend, because it rejects moral absolutism. Rather than legislating a binary right or wrong, it preserves the illegality of the act — signaling its gravity — while simultaneously creating a structured space for physicians to act when they have no other defensible option. It's regulatory pragmatism rather than permissiveness.
Alex: [curious] Though if the review process is that consequential, does it create a chilling effect in the other direction? Physicians avoiding a procedure even when it might be the most humane choice, simply because they fear the scrutiny? [[RP_SECTION:limitations-and-trade-offs|Limitations and Trade-offs]]
Sam: [measured, acknowledging the weight] That's the primary limitation the authors flag explicitly. The prospect of a criminal referral is a powerful disincentive, and the concern is that some patients may remain in intractable suffering despite the existence of a legal framework — not because the framework prohibits action, but because the personal and professional risk of invoking it feels too high. It's a genuine trade-off: the same mechanism that suppresses misuse may also suppress appropriate use.
Alex: [deliberate] So the system is calibrated to err on the side of caution. Which is probably part of why the case count dropped so sharply — but it also means the floor on under-provision is hard to measure.
Sam: [broader perspective] Exactly, and that's the honest limitation of the Dutch experience as a model. What you can observe is the reported case rate. What you can't easily observe is the counterfactual — how many cases that might have met the criteria weren't brought forward at all. The authors don't resolve that, and it's where a careful reader should push back.
Alex: [reflective] It reframes the governance question entirely. Rather than asking whether something should be legal, the Dutch model asks: if it occurs, how do we ensure it happens with the highest level of accountability and clinical rigor?
Sam: [quiet conviction] And that shift — from binary prohibition to continuous, case-by-case oversight — is the most transferable lesson for other jurisdictions. The evidence here suggests that in highly sensitive areas of medicine, transparency and peer review can be more effective at constraining problematic practice than outright prohibition. Whether that trade-off is acceptable depends on values that regulation alone can't settle. But the Dutch data, at minimum, challenges the assumption that formal protocols inevitably expand the practices they govern. Thanks for listening to ResearchPod.